(11bR)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-双[3,5-双[3,5-双(三氟甲基)苯基]苯基]-4-氧化物-二萘酚[2,1-d:1',2'-f][1,3,2]二氧磷,98% (11bR)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-bis[3,5-bis[3,5-bis(trifluoromethyl)phenyl]phenyl]-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98%
-
(11bS)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-双[3,5-双[3,5-双(三氟甲基)苯基]苯基]-4-氧化物-二萘酚[2,1-d:1',2'-f][1,3,2]二氧磷,98%,(99%ee) (11bS)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-bis[3,5-bis[3,5-bis(trifluoromethyl)phenyl]phenyl]-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98%, (99% ee)
ZMR-15-0558 | 100mg
-
(11bS)-2,6-双[3,5-双(三氟甲基)苯基]-8,9,10,11,12,13,14,15-八氢-4-羟基-4-氧化物二萘[2-,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bS)-2,6-Bis[3,5-bis(trifluoromethyl)phenyl]-8,9,10,11,12,13,14,15-octahydro-4-hydroxy-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98%, (99% ee)
ZMR-15-1377 | 100mg
-
(11bR)-2,6-双(3,5-二甲基苯基)-8,9,10,11,12,13,14,15-八氢-4-羟基-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bR)-2,6-Bis(3,5-dimethylphenyl)-8,9,10,11,12,13,14,15-octahydro-4-hydroxy-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98%, (99% ee)
ZMR-15-1373 | 100mg
-
(11bR)-2,6-双[3,5-双(1,1-二甲基乙基)苯基]-4-羟基-4-氧化物-二萘酚[2,1-d:1',2'-f][1,3,2]二氧磷,98% (11bR)-2,6-Bis[3,5-bis(1,1-dimethylethyl)phenyl]-4-hydroxy-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98%
ZMR-15-0562 | 100mg
-
N-[(11bR)-2,6-bis[3,5-bis(trifluoromethyl)phenyl]-8,9,10,11,12,13,14,15-octahydro-4-oxidodinaphtho[2,1-d:1',2'-f][1,3,2]dioxapho N-[(11bR)-2,6-bis[3,5-bis(trifluoromethyl)phenyl]-8,9,10,11,12,13,14,15-octahydro-4-oxidodinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yl]-1,1,1-trifluoro-Methanesulfonamide
T24080-100mg | 100mg
-
(11bS)-2,6-双(3,5-二甲基苯基)-8,9,10,11,12,13,14,15-八氢-4-羟基-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bS)-2,6-Bis(3,5-dimethylphenyl)-8,9,10,11,12,13,14,15-octahydro-4-hydroxy-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98%, (99% ee)
ZMR-15-1374 | 100mg
-
(11BR)-2,6-双(3,5-双(三氟甲基)苯基)-4-羟基二萘酚[2,1-D:1,2-F][1,3,2]二氧膦-4-氧化物|(11BR)-2,6-Bis(3,5-Bis(Trifluoromethyl)Phenyl)-4-Hydroxydinaphtho[2,1-D:1,2-F][1,3,2]Dioxaphosphepine 4-Oxide|878111-17-2|Sigma-Aldrich|95%|100MG (11BR)-2,6-Bis(3,5-Bis(Trifluoromethyl)Phenyl)-4-Hydroxydinaphtho[2,1-D:1,2-F][1,3,2]Dioxaphosphepine 4-Oxide
Sigma-Aldrich-S#681520-100MG | 100MG
中文名称:(11bR)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-双[3,5-双[3,5-双(三氟甲基)苯基]苯基]-4-氧化物-二萘酚[2,1-d:1',2'-f][1,3,2]二氧磷,98%
英文名称:(11bR)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-bis[3,5-bis[3,5-bis(trifluoromethyl)phenyl]phenyl]-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98%
分子式:C64H39F24O4P;分子量:1358.90。
您正在浏览的产品:(11bR)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-双[3,5-双[3,5-双(三氟甲基)苯基]苯基]-4-氧化物-二萘酚[2,1-d:1',2'-f][1,3,2]二氧磷,98%
手机版:(11bR)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-双[3,5-双[3,5-双(三氟甲基)苯基]苯基]-4-氧化物-二萘酚[2,1-d:1',2'-f][1,3,2]二氧磷,98%
本公司销售的所有产品仅供实验科研使用,不用于人体及临床诊断。
检出限(LOD):≤0.1 μg/L(以标准品计)
定量限(LOQ):≤0.5 μg/L(需验证基质效应)
1. 空白基质加标样品:添加浓度需覆盖目标物实际浓度范围
2. 平行样比例:每批次≥10%
3. 标准曲线线性:R²≥0.995
1. 样品前处理:需使用含0.1%甲酸的乙腈溶液萃取
2. 色谱条件:C18色谱柱,流动相为甲醇-水(含5 mmol/L乙酸铵)梯度洗脱
3. 质谱采集:正离子模式,扫描范围m/z 200-2000
1. 该化合物对光敏感,需避光操作
2. 含磷基团易与金属离子络合,须使用惰性材质容器
3. 质谱分析时需注意同位素峰分布特征以确认分子式
以上信息仅供参考,请以相应标准的原文为准!